Oxybutynin
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
- Oxybutynin
- Oxybutynin: From Overactive Bladder to Low Compliance Bladder (Neurogenic Bladder Dysfunction)
Oxybutynin: From Overactive Bladder to Low Compliance Bladder (Neurogenic Bladder Dysfunction)
One-Sentence Summary
Oxybutynin is a well-established antimuscarinic (M3 receptor antagonist) whose established clinical use is overactive bladder/urinary incontinence, though this evidence pack does not contain formal licensing or indication-text data confirming that. Among the 10 indications TxGNN predicted for this drug, Low Compliance Bladder is the only candidate with meaningful supporting evidence — 2 clinical trials (including 1 Phase 3 RCT) and 20 publications, several of which are cohort studies and a systematic review on intravesical oxybutynin in neurogenic bladder. The drug’s single highest-scoring TxGNN prediction (restless legs syndrome, 99.74%) has zero supporting evidence and no plausible mechanism, illustrating why this report leads with the best-evidenced candidate rather than the top-ranked score.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack (no licenses on file); commonly known clinical use is overactive bladder / urinary incontinence |
| Predicted New Indication | Low Compliance Bladder (neurogenic bladder dysfunction) |
| TxGNN Prediction Score | 97.88% |
| Evidence Level | L2 |
| EU Market Status | Not Marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed original MOA documentation is currently a data gap (DG002, High severity). Based on the mechanistic rationale captured in this evidence pack, oxybutynin is an antimuscarinic (M3 receptor) antagonist with direct musculotropic antispasmodic action on detrusor smooth muscle — this is the pharmacological basis of its established use in overactive bladder.
Low compliance bladder is, at its core, a state of abnormally reduced bladder wall distensibility, most commonly driven by detrusor overactivity/hypertonicity or fibrosis in neurogenic bladder (e.g., spina bifida, spinal cord injury, posterior urethral valves). Because oxybutynin’s core mechanism directly reduces detrusor overactivity and increases compliance, the mechanistic fit here is strong — considerably stronger than most of TxGNN’s other predictions for this drug. Intravesical oxybutynin is already established off-label practice in pediatric neurogenic bladder, meaning this “new indication” largely represents formalization of existing clinical practice rather than a mechanistically novel repurposing.
For context, the drug’s highest TxGNN score (restless legs syndrome, 99.74%) has no mechanistic plausibility (RLS pathology is dopaminergic/iron-related, unrelated to muscarinic antagonism) and zero clinical/literature support — it is a pure statistical artifact and was scored Hold at stage S0. Several other candidates (gastroduodenitis, NSIAD, faciodigitogenital syndrome, familial episodic pain syndrome, transient tic disorder) are similarly unsupported. Peptic ulcer disease evidence is actively unfavorable — a 1990 case report describes oxybutynin-inducing reflux esophagitis via lowered LES tone, the opposite of a therapeutic signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07027020 | Phase 3 | Not yet recruiting | 60 | Randomized, prospective, multi-center trial of intravesical oxybutynin efficacy in children with neurogenic bladder dysfunction (spina bifida) with poor compliance and overactivity |
| NCT05745584 | N/A | Unknown | 15 | Prospective paired comparison of mirabegron vs. anticholinergics (incl. oxybutynin) on bladder compliance in neurogenic bladder patients |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18639290 | 2008 | Systematic Review | J Urol | Systematic review of intravesical oxybutynin in children with poorly compliant neurogenic bladder — supports effectiveness and tolerability |
| 30937115 | 2019 | Long-term Cohort | J Clin Med Res | Long-term efficacy, safety, and tolerability of modified intravesical oxybutynin in pediatric neurogenic bladder |
| 22910256 | 2012 | Cohort (newborns) | J Urol | Early oxybutynin administration improves bladder function/clinical outcomes in newborns with posterior urethral valves |
| 9307522 | 1997 | Cohort | Br J Obstet Gynaecol | Medium-term subjective efficacy of treatment (incl. anticholinergics) in women with detrusor instability and low bladder compliance |
| 8015832 | 1994 | Cohort | Paraplegia | Intravesical oxybutynin in 17 neuropathic bladder patients: bladder capacity increased from 132±45 mL to 193±71 mL post-instillation (p<0.05) |
| 26676285 | 2010 | Review | Lower Urin Tract Symptoms | Management of low compliant bladder in spinal cord injured patients, defining hypocompliance range (1.0–20.0 mL/cmH2O) |
| 12483499 | 2002 | Case Series | Spinal Cord | Prospective urodynamic study establishing significance of low compliance bladder in cauda equina injury |
| 16465186 | 2006 | Review (mechanism) | Br J Pharmacol | Mechanistic review of muscarinic (M2/M3) receptors in bladder function — pharmacological basis for antimuscarinic therapy |
| 40690105 | 2026 | Systematic Review/Meta-analysis | Int Urol Nephrol | TENS vs. oxybutynin in pediatric overactive bladder — confirms oxybutynin as standard-of-care comparator |
| 28431215 | 2017 | Cohort | J Pediatr (Rio J) | Early treatment (20-year experience) improves urodynamic prognosis in neurogenic voiding dysfunction |
EU Market Information
No marketing authorizations are on file for oxybutynin in this jurisdiction — market status is recorded as Not marketed (Not Marketed) with 0 total licenses. No EMA product/authorization data could be extracted.
Safety Considerations
Please refer to the SmPC for safety information.
Note: Retrieval of TFDA label warnings and contraindications (DG001) is flagged as a Blocking data gap — this evidence pack cannot yet support a formal S1 safety pre-assessment. No drug-drug interaction data was found (query status: not_found).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Low Compliance Bladder reaches L2 evidence with mechanistically coherent, converging cohort and systematic-review data supporting intravesical/systemic oxybutynin’s ability to improve bladder compliance in neurogenic bladder populations, plus an ongoing Phase 3 RCT (NCT07027020) designed to confirm this in a pediatric population. However, a blocking safety data gap (DG001) prevents full risk assessment, so this cannot yet be a plain “Go.”
To proceed, the following is needed:
- TFDA/SmPC label warnings and contraindications (DG001, blocking — required before S1 safety evaluation)
- Formal drug mechanism of action (MOA) documentation from DrugBank (DG002)
- Local/EU marketing authorization status confirmation (currently 0 licenses on file)
- Route-of-administration compatibility assessment (oral vs. intravesical formulation availability)
- Monitor NCT07027020 (Phase 3, not yet recruiting) for enrollment start and eventual results
Screened out (Hold): The other 9 TxGNN predictions for this drug — including the single highest-scoring one, restless legs syndrome (99.74%) — lack both clinical/literature evidence and mechanistic plausibility, or (in the case of peptic ulcer disease) show a documented adverse signal rather than a therapeutic one. These are not recommended for further investment at this time.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.